Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Market for Insomnia Treatments to Expand to US$1 Bil. by 2019 in Japan: Datamonitor
August 16, 2010
- Taiyo Yakuhin Posts Measures to Improve Manufacturing Practice on Its Website
August 16, 2010
- Eisai: Sales Up 5% Driven by Good Sales of Aricept
August 16, 2010
- Seikagaku: Sales Remain Virtually Unchanged
August 16, 2010
- Sales of Ethical Drugs Up 2.3% in June: Crecon Report
August 16, 2010
- ARQ 197 to Enter PIII for NSCLC: Daiichi Sankyo, ArQule
August 16, 2010
- MTPC: Sales, Profits Up despite Biz Suspension
August 16, 2010
- JCR Pharmaceuticals: Upfront Payment from GSK Boosts Sales
August 16, 2010
- Market for Antidepressants in Japan Part II (1)
August 16, 2010
- SSP to Place Top Priority on Profit Ratio: President Shiono
August 16, 2010
- DSP: Former Sepracor Boosts Sales by 54.1%
August 16, 2010
- Wakamoto: Net Loss Increases to ¥132 Mil.
August 16, 2010
- Market for Antidepressants in Japan Part II (2)
August 16, 2010
- Daiichi Sankyo Aims to Enter Vaccine Market in Emerging Countries
August 16, 2010
- Shionogi: Crestor Pulls Up Sales 17.5%
August 16, 2010
- Medipal HD: Sales up 4.7% with Strong Increases in Profits
August 16, 2010
- 5 APIs, 7 Indications to Be Applied for Based on Data from Public Domain
August 16, 2010
- Taisho: Self-Medication Makes Up for Slump of Ethical Drugs
August 16, 2010
- Alfresa: Profits Up as a Result of Firm Pricing Policy
August 16, 2010
- Korosho Posts Its Policy for Assessment of Research Projects
August 16, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…